|
Investor and Media
Relations:
Marty Tullio, Managing Partner
McCloud Communications, LLC
949.553.9748
marty@mccloudcommunications.com
|
|
Victory by Overwhelming Majority for CNS
Response Board
at Annual Meeting of
Stockholders
CEO George Carpenter Lauds Clear Mandate From
Shareholders
Costa Mesa,
CA – September 29, 2009 – CNS Response,
Inc. (OTCBB: CNSO) today
announced the voting results of its Annual Meeting of Shareholders held
September 29, 2009 in Newport Beach, California. Present at the
meeting in person or by
proxy were holders of 26,490,888, or 63.4 percent of common stock entitled to
vote as of the record date of August 27, 2009.
At the meeting, George Carpenter, Henry
Harbin, M.D., David Jones, John Pappajohn, Jerome Vaccaro, M.D. and Tommy Thompson were elected by greater
than 99 percent of the shares voting at the
meeting. More than 80 percent of the shares of the Company, other
than those owned by Len Brandt and his family, voted in favor of the
Company’s Board of
Directors.
George Carpenter, CEO of CNS, expressed
gratitude to the stockholders of CNS for their clear and decisive vote of
confidence for the current management team, “We are delighted to have received such
an overwhelming majority of the voted shares. We accept
this mandate from the stockholders of the
Company to continue our efforts and we intend to justify the faith and
confidence placed in us by our supporters.”
Addressing the recent challenges to the
Board by Len Brandt, Mr. Carpenter noted, “Today, our stockholders clearly affirmed that they believe
in the Company’s Board and management team, and that
Len Brandt’s destructive tactics need to
stop.”
Under the terms of a status quo order
issued by the Delaware Court of Chancery, in connection with the action by
Len Brandt seeking to
enforce the results of his purported September 4th stockholder meeting George
Carpenter, Henry Harbin, M.D., David Jones, John Pappajohn, Jerome Vaccaro, M.D.
Tommy Thompson, and Len Brandt will serve as status quo directors until the
case is concluded.
Mr. Carpenter concluded, “We will continue to conduct our business
as usual. We will continue to complete our trial and to bring our
product to market. We look forward to a bright future and more
victories to follow.”
About CNS Response
Today, most physicians are able to base
treatment on objective test data, such as EKGs, MRIs, blood tests,
etc. Broadly speaking, such advances have not yet come to those
physicians practicing psychiatry.
CNS Response has developed a patented
data-analysis capability
that, with the help of a simple, non-invasive EEG, will analyze a
patient’s brain waves and compare the results to
an extensive patient
-more-
Victory by Overwhelming Majority for CNS
Response Board at Annual Meeting of Stockholders
Page 2
outcomes database. The process produces
a rEEG® report providing a
psychiatrist with guidance to personalize medication regimens for a patient,
based on the patient’s own brain physiology. To read more
about the benefits this patented technology provides physicians, patients and insurers,
please visit the CNS Response website, www.cnsresponse.com.
Safe Harbor Statement Under the Private
Securities Litigation Reform Act of 1995
Except for the historical
information contained
herein, the matters discussed are forward-looking statements made pursuant to
the safe harbor provisions of the Private Securities Litigation Reform Act of
1995, as amended. These statements involve risks and uncertainties as set forth
in the Company's filings with the
Securities and Exchange Commission. These risks and uncertainties could cause
actual results to differ materially from any forward-looking statements made
herein.
# # #
